Bristol Myers Squibb's Q4 earnings and revenue exceeded Wall Street expectations, driven by robust sales growth of its new pharmaceutical products.

Bristol Myers Squibb's Q4 financial results exceeded expectations, with adjusted earnings per share at $1.70 and revenue at $11,48 billion, exceeding the expected $11.19 billion.

Bristol Myers Squibb's Q4 financial results exceeded expectations, primarily due to strong sales performance of newly introduced pharmaceuticals like Reblozyl and Opdualag.

Bristol Myers Squibb's Q4 financial results showed a 66% sales increase to $1.07 billion, surpassing the $645 million achieved in the same period last year.

The financial results for the fourth quarter of Bristol Myers Squibb exceeded expectations, but the company's profitability decreased when compared to the previous year.

Bristol Myers provided a comprehensive forecast for 2024, expecting higher-than-anticipated profits for the fiscal year. 

Bristol Myers Squibb's Q4 financial results exceeded expectations, with sales growth partially attributed to Eliquis and Opdivo, with Eliquis generating $2.87 billion in sales.

Bristol Myers Squibb's Q4 financial results exceeded expectations, with Opdivo's revenue increasing by 8% and Revlimid's sales decline exceeding FactSet's anticipated $1.33 billion.